Naltrexone in Borderline Personality Disorder

• Status: Terminated
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to investigate whether naltrexone reduces the intensity and duration of flashbacks and dissociative states in patients with borderline personality disorder.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Central Institute of Mental Health, Mannheim
• Treatments: Naltrexone

Criteria

Inclusion Criteria:

• In- and Outpatients:Borderline personality disorder according to the Diagnostic and Statistical Manual for Mental Disorders, 4.Edition (DSM IV)

• DES-(Dissociative Experience Scale)-score: > or equal 18 according to amendment4 (former value according to amendment 2 was > or equal 25).

• Urinary test of opiates negative

• No psychopharmacological treatment for two weeks prior to study (fluoxetine four weeks)

• No Lithium for two months

Exclusion Criteria:

• Lifetime diagnosis of psychotic disorder

• Current major depressive disorder (MDD)

• Lifetime diagnosis opioid dependence or current opioid abuse (10 to 7 days prior to study)

• Comedication with opioid analgetics

• Known naltrexone intolerance

• Liver disease

• Pregnancy and lactation period

• Other severe medical or neurological diseases

• Simultaneous participation in another study